Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
Milou M F SchuurbiersZhongyun HuangSenglor SaeleeManana JaveyLeonie de VisserDaan van den BroekMichel van den HeuvelAlexander F LovejoyKim MonkhorstDaniel KlassPublished in: Journal for immunotherapy of cancer (2022)
Plasma samples with high bTMB values are highly correspondent with tTMB, whereas bTMB low results may also be the result of low tumor burden at earlier stages of disease as well as poorly shedding tumors. For advanced stages of disease, PPA (sensitivity) of bTMB is satisfactory in comparison to tTMB, even when using a panel of less than 600 kb, warranting consideration of bTMB as a predictive biomarker for patients with NSCLC eligible for immunotherapy in the future.